Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <55 mg/dL

Takamasa Iwai; Yu Kataoka; Stephen J. Nicholls; Rishi Puri; Shunsuke Murata; Kunihiro Nishimura; Kota Murai; Satoshi Kitahara; Kenichiro Sawada; Hideo Matama; Satoshi Honda; Kensuke Takagi; Masashi Fujino; Shuichi Yoneda; Fumiyuki Otsuka; Kensaku Nishihira; Yasuhide Asaumi; Yoshihiro Miyamoto; Satoshi Yasuda; Teruo Noguchi

doi:10.1016/j.jcmg.2022.02.005

Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <55 mg/dL

Takamasa Iwai, Yu Kataoka, Stephen J. Nicholls, Rishi Puri, Shunsuke Murata, Kunihiro Nishimura, Kota Murai, Satoshi Kitahara, Kenichiro Sawada, Hideo Matama, Satoshi Honda, Kensuke Takagi, Masashi Fujino, Shuichi Yoneda, Fumiyuki Otsuka, Kensaku Nishihira, Yasuhide Asaumi, Yoshihiro Miyamoto, Satoshi Yasuda, Teruo Noguchi

Research output: Contribution to journal › Letter › Other › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	1166-1169
Number of pages	4
Journal	JACC: Cardiovascular Imaging
Volume	15
Issue number	6
DOIs	https://doi.org/10.1016/j.jcmg.2022.02.005
Publication status	Published - Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcmg.2022.02.005

Cite this

Iwai, T., Kataoka, Y., Nicholls, S. J., Puri, R., Murata, S., Nishimura, K., Murai, K., Kitahara, S., Sawada, K., Matama, H., Honda, S., Takagi, K., Fujino, M., Yoneda, S., Otsuka, F., Nishihira, K., Asaumi, Y., Miyamoto, Y., Yasuda, S., & Noguchi, T. (2022). Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <55 mg/dL. JACC: Cardiovascular Imaging, 15(6), 1166-1169. https://doi.org/10.1016/j.jcmg.2022.02.005

@article{89cad49f95b34574a96f54a040c5f52f,

title = "Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <55 mg/dL",

author = "Takamasa Iwai and Yu Kataoka and Nicholls, {Stephen J.} and Rishi Puri and Shunsuke Murata and Kunihiro Nishimura and Kota Murai and Satoshi Kitahara and Kenichiro Sawada and Hideo Matama and Satoshi Honda and Kensuke Takagi and Masashi Fujino and Shuichi Yoneda and Fumiyuki Otsuka and Kensaku Nishihira and Yasuhide Asaumi and Yoshihiro Miyamoto and Satoshi Yasuda and Teruo Noguchi",

note = "Funding Information: The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Dr Kataoka has received research support from Nipro and Abbott, and honoraria from Nipro, Abbott, Kowa, Amgen, Sanofi, Astellas, Takeda, and Daiichi-Sankyo. Dr Nicholls is a recipient of a Principal Research Fellowship from the National Health and Medical Research Council of Australia, has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron, and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. Dr Puri has received speaker fees from Amgen and Sanofi, served as a consultant for Cerenis, Medtronic, Philips, Boston Scientific, and Shockwave, is on advisory boards for Centerline Biomedical, Medtronic, and Bioventrix, and holds minor equity in Centerline Biomedical. Dr Otsuka is a recipient of a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (19K08571) and received support and honoraria from Abbott Medical Japan LCC, Amgen Astellas BioPharma KK, Bayer Yakuhin, Boston Scientific Corporation, Bristol-Myers Squibb, Daiichi Sankyo Company, Kowa Pharmaceutical Co, Nipro Corporation, Novartis Pharma KK, Otsuka Pharmaceutical Co, Pfizer Japan, Sanofi KK, Takeda Pharmaceutical Company Limited, and Terumo Corporation. Dr Yasuda has received speaker fees from Bristol-Myers Squibb, Bayer, and Daiichi-Sankyo; and is affiliated with Abbott, Terumo, Nihon-Kohden, Medtronic, Japan Lifeline, Otsuka, Ono, Boehringer Ingelheim, Takeda, Kowa, Zeon, Shionogi, Nippon-Shinyaku, Mochida, and Tesco. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Dr Kataoka has received research support from Nipro and Abbott, and honoraria from Nipro, Abbott, Kowa, Amgen, Sanofi, Astellas, Takeda, and Daiichi-Sankyo. Dr Nicholls is a recipient of a Principal Research Fellowship from the National Health and Medical Research Council of Australia, has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron, and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. Dr Puri has received speaker fees from Amgen and Sanofi, served as a consultant for Cerenis, Medtronic, Philips, Boston Scientific, and Shockwave, is on advisory boards for Centerline Biomedical, Medtronic, and Bioventrix, and holds minor equity in Centerline Biomedical. Dr Otsuka is a recipient of a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (19K08571) and received support and honoraria from Abbott Medical Japan LCC, Amgen Astellas BioPharma KK, Bayer Yakuhin, Boston Scientific Corporation, Bristol-Myers Squibb, Daiichi Sankyo Company, Kowa Pharmaceutical Co, Nipro Corporation, Novartis Pharma KK, Otsuka Pharmaceutical Co, Pfizer Japan, Sanofi KK, Takeda Pharmaceutical Company Limited, and Terumo Corporation. Dr Yasuda has received speaker fees from Bristol-Myers Squibb, Bayer, and Daiichi-Sankyo; and is affiliated with Abbott, Terumo, Nihon-Kohden, Medtronic, Japan Lifeline, Otsuka, Ono, Boehringer Ingelheim, Takeda, Kowa, Zeon, Shionogi, Nippon-Shinyaku, Mochida, and Tesco. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2022",

month = jun,

doi = "10.1016/j.jcmg.2022.02.005",

language = "English",

volume = "15",

pages = "1166--1169",

journal = "JACC: Cardiovascular Imaging",

issn = "1936-878X",

publisher = "Elsevier",

number = "6",

}

Iwai, T, Kataoka, Y, Nicholls, SJ, Puri, R, Murata, S, Nishimura, K, Murai, K, Kitahara, S, Sawada, K, Matama, H, Honda, S, Takagi, K, Fujino, M, Yoneda, S, Otsuka, F, Nishihira, K, Asaumi, Y, Miyamoto, Y, Yasuda, S & Noguchi, T 2022, 'Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <55 mg/dL', JACC: Cardiovascular Imaging, vol. 15, no. 6, pp. 1166-1169. https://doi.org/10.1016/j.jcmg.2022.02.005

TY - JOUR

T1 - Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <55 mg/dL

AU - Iwai, Takamasa

AU - Kataoka, Yu

AU - Nicholls, Stephen J.

AU - Puri, Rishi

AU - Murata, Shunsuke

AU - Nishimura, Kunihiro

AU - Murai, Kota

AU - Kitahara, Satoshi

AU - Sawada, Kenichiro

AU - Matama, Hideo

AU - Honda, Satoshi

AU - Takagi, Kensuke

AU - Fujino, Masashi

AU - Yoneda, Shuichi

AU - Otsuka, Fumiyuki

AU - Nishihira, Kensaku

AU - Asaumi, Yasuhide

AU - Miyamoto, Yoshihiro

AU - Yasuda, Satoshi

AU - Noguchi, Teruo

N1 - Funding Information: The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Dr Kataoka has received research support from Nipro and Abbott, and honoraria from Nipro, Abbott, Kowa, Amgen, Sanofi, Astellas, Takeda, and Daiichi-Sankyo. Dr Nicholls is a recipient of a Principal Research Fellowship from the National Health and Medical Research Council of Australia, has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron, and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. Dr Puri has received speaker fees from Amgen and Sanofi, served as a consultant for Cerenis, Medtronic, Philips, Boston Scientific, and Shockwave, is on advisory boards for Centerline Biomedical, Medtronic, and Bioventrix, and holds minor equity in Centerline Biomedical. Dr Otsuka is a recipient of a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (19K08571) and received support and honoraria from Abbott Medical Japan LCC, Amgen Astellas BioPharma KK, Bayer Yakuhin, Boston Scientific Corporation, Bristol-Myers Squibb, Daiichi Sankyo Company, Kowa Pharmaceutical Co, Nipro Corporation, Novartis Pharma KK, Otsuka Pharmaceutical Co, Pfizer Japan, Sanofi KK, Takeda Pharmaceutical Company Limited, and Terumo Corporation. Dr Yasuda has received speaker fees from Bristol-Myers Squibb, Bayer, and Daiichi-Sankyo; and is affiliated with Abbott, Terumo, Nihon-Kohden, Medtronic, Japan Lifeline, Otsuka, Ono, Boehringer Ingelheim, Takeda, Kowa, Zeon, Shionogi, Nippon-Shinyaku, Mochida, and Tesco. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Funding Information: The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Dr Kataoka has received research support from Nipro and Abbott, and honoraria from Nipro, Abbott, Kowa, Amgen, Sanofi, Astellas, Takeda, and Daiichi-Sankyo. Dr Nicholls is a recipient of a Principal Research Fellowship from the National Health and Medical Research Council of Australia, has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx, and Sanofi-Regeneron, and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, and Novo Nordisk. Dr Puri has received speaker fees from Amgen and Sanofi, served as a consultant for Cerenis, Medtronic, Philips, Boston Scientific, and Shockwave, is on advisory boards for Centerline Biomedical, Medtronic, and Bioventrix, and holds minor equity in Centerline Biomedical. Dr Otsuka is a recipient of a Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science (19K08571) and received support and honoraria from Abbott Medical Japan LCC, Amgen Astellas BioPharma KK, Bayer Yakuhin, Boston Scientific Corporation, Bristol-Myers Squibb, Daiichi Sankyo Company, Kowa Pharmaceutical Co, Nipro Corporation, Novartis Pharma KK, Otsuka Pharmaceutical Co, Pfizer Japan, Sanofi KK, Takeda Pharmaceutical Company Limited, and Terumo Corporation. Dr Yasuda has received speaker fees from Bristol-Myers Squibb, Bayer, and Daiichi-Sankyo; and is affiliated with Abbott, Terumo, Nihon-Kohden, Medtronic, Japan Lifeline, Otsuka, Ono, Boehringer Ingelheim, Takeda, Kowa, Zeon, Shionogi, Nippon-Shinyaku, Mochida, and Tesco. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85131145447&partnerID=8YFLogxK

U2 - 10.1016/j.jcmg.2022.02.005

DO - 10.1016/j.jcmg.2022.02.005

M3 - Letter

C2 - 35680226

AN - SCOPUS:85131145447

SN - 1936-878X

VL - 15

SP - 1166

EP - 1169

JO - JACC: Cardiovascular Imaging

JF - JACC: Cardiovascular Imaging

IS - 6

ER -

Phenotypic Features of Coronary Atheroma in Diabetic and Nondiabetic Patients With Low-Density Lipoprotein Cholesterol <55 mg/dL

UN SDGs

Access to Document

Other files and links

Cite this